



4-12-05

889642
\$

Customer ID: 27123

Docket No. 3828-4001US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Cohava GELBER

Group Art Unit: 1642

Serial No.: 10/015,728

Examiner: Misook Yu

Filed: November 1, 2001

For: MONOCLONAL ANTIBODIES AND CELL SURFACE ANTIGENS FOR THE
DETECTION AND TREATMENT OF SMALL CELL LUNG CANCER (SCLC)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

04/13/2005 BABRAHA1 00000030 10015728

01 FC:1806

180.00 OP

Sir:

This Information Disclosure Statement is filed in accordance with 37 C.F.R.

§§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application.

The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:
2. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3. ☐ Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. _____, filed _____.
4. ☐ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:
☐ 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or

- ☐ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
- ☐ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
- ☐ 37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.
5. ☐ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6. ☒ A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):
- ☒ A check in the amount of \$180.00 is enclosed in payment of the fee.
- ☐ Charge the fee to Deposit Account No. 13-4500, Order No. _____. A
DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7. ☐ A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:
- a. one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and
- b. the fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 below.
8. ☐ This Information Disclosure Statement is being filed in compliance with:
- a. ☐ 37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);
- b. ☐ 37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).

- c. ☐ The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 below.
9. ☐ I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- ☐ I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
10. ☒ This document is accompanied by ☒ a Search Report ☐ Communication which was cited in a corresponding ☐ PCT or ☐ Foreign counterpart application
11. ☒ A check in the amount of \$180.00 is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p).
- ☐ Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3828-4001US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

By:


Paula K. Wittmayer
Registration No. 53,785

Dated: April 11, 2005

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
3 World Financial Center
New York, NY 10281-2101
(212) 415-8700 Telephone
(212) 415-8701 Facsimile



| | | |
|---|------------------|-----------------|
| FORM PTO-1449 SUPPLEMENTAL INFORMATION DISCLOSURE CITATION | Attorney Docket: | Serial No.: |
| | 3828-4001US1 | 10/015,728 |
| | Applicant: | |
| | Cohava GELBER | |
| | Filing Date: | Group Art Unit: |
| | November 1, 2001 | 1642 |


| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|--|---------------|------------|-----------------|-------|-----------|-------------|
| Examiner Initial | | Patent Number | Issue Date | Name | Class | Sub-Class | Filing Date |
| | | 4,585,742 | 04/29/86 | Bernal | | | 12/14/83 |
| | | 5,665,864 | 09/09/97 | Quaranta et al. | | | 09/2/94 |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|--|---------------|------------------|---------|-------|-----------|--|
| Examiner Initial | | Patent Number | Publication Date | Country | Class | Sub-Class | Translation |
| | | | | | | | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| | | | | | | | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| | | | | | | | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| | | | | | | | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| | | | | | | | <input type="checkbox"/> Yes <input type="checkbox"/> No |

| OTHER DOCUMENTS (Including Author, Title, Date, etc.) | | |
|---|--|--|
| | | B. Birk et al., "Cobas® Core CA 19-9 II EIA: New CA 19-9 Enzyme Immunoassay with High Correlation to Radioimmunoassays", AntiCancer Research 17:2911-2914 (1997) |
| | | Y. Fujii et al., "Characterization of a murine monoclonal antibody, 5D-4, reacting with pancreatic cancers and islets of Langerhans", Biomed & Pharmacother (1992) 46, 405-411 |
| | | J. Taylor et al., "Detection of Somatostatin Receptor Subtype 2 (SSTR2) in Established Tumors and Tumor Cell Lines: Evidence for SSTR2 Heterogeneity", Peptides, Vol. 15, No. 7, pp. 1229-1236 (1994) |
| | | J. Chin et al. "Reactivity of Monoclonal Anti-Human Pancreatic Carcinoma Antibodies AR2-20 and AR1-28 With Tumors of Nonpancreatic Origin", American Journal of Pathology, vol. 126, no. 1 1987, pp. 183-193 |
| | | |
| | | |
| | | |
| | | |

| | |
|----------|-----------------|
| Examiner | Date Considered |
|----------|-----------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.



FORM PTO-1449

SUPPLEMENTAL INFORMATION
DISCLOSURE CITATIONAttorney Docket:
3828-4001US1Serial No.:
10/015,728Applicant:
Cohava GELBERFiling Date:
November 1, 2001Group Art Unit:
1642

U.S. PATENT DOCUMENTS

| Examiner Initial | Patent Number | Issue Date | Name | Class | Sub-Class | Filing Date |
|------------------|---------------|------------|-----------------|-------|-----------|-------------|
| | 4,585,742 | 04/29/86 | Bernal | | | 12/14/83 |
| | 5,665,864 | 09/09/97 | Quaranta et al. | | | 09/2/94 |
| | | | | | | |
| | | | | | | |
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initial | Patent Number | Publication Date | Country | Class | Sub-Class | Translation |
|------------------|---------------|------------------|---------|-------|-----------|--|
| | | | | | | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| | | | | | | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| | | | | | | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| | | | | | | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| | | | | | | <input type="checkbox"/> Yes <input type="checkbox"/> No |

OTHER DOCUMENTS (Including Author, Title, Date, etc.)

| | |
|--|--|
| | B. Birk et al., "Cobas® Core CA 19-9 II EIA: New CA 19-9 Enzyme Immunoassay with High Correlation to Radioimmunoassays", AntiCancer Research 17:2911-2914 (1997) |
| | Y. Fujii et al., "Characterization of a murine monoclonal antibody, 5D-4, reacting with pancreatic cancers and islets of Langerhans", Biomed & Pharmacother (1992) 46, 405-411 |
| | J. Taylor et al., "Detection of Somatostatin Receptor Subtype 2 (SSTR2) in Established Tumors and Tumor Cell Lines: Evidence for SSTR2 Heterogeneity", Peptides, Vol. 15, No. 7, pp. 1229-1236 (1994) |
| | J. Chin et al. "Reactivity of Monoclonal Anti-Human Pancreatic Carcinoma Antibodies AR2-20 and AR1-28 With Tumors of Nonpancreatic Origin", American Journal of Pathology, vol. 126, no. 1 1987, pp. 183-193 |
| | |
| | |
| | |
| | |

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.